Lafora progressive myoclonous epilepsy (Lafora disease; LD) is caused by mutations in the EPM2A gene encoding a dual specificity protein phosphatase named laforin. Our analyses on the Epm2a gene knock-out mice, which developed most of the symptoms of LD, reveal the presence of hyperphosphorylated Tau protein (Ser396 and Ser202) as neurofibrillary tangles (NFTs) in the brain. Intriguingly, NFTs were also observed in the skeletal muscle tissues of the knock-out mice. The hyperphosphorylation of Tau was associated with increased levels of the active form of GSK3β. The observations on Tau protein were replicated in cell lines using laforin overexpression and knockdown approaches. We also show here that laforin and Tau proteins physically interact and that the interaction was limited to the phosphatase domain of laforin. Finally, our in vitro and in vivo assays demonstrate that laforin dephosphorylates Tau, and therefore laforin is a novel Tau phosphatase. Taken together, our study suggests that laforin is one of the critical regulators of Tau protein, that the NFTs could underlie some of the symptoms seen in LD, and that laforin can contribute to the NFT formation in Alzheimer disease and other tauopathies.

Lafora disease (LD) is an autosomal recessive and a fatal form of progressive myoclonous epilepsy characterized by the presence of Lafora polyglucosan bodies in the affected tissues (1). The symptoms of LD include stimulus-sensitive epilepsy, dementia, ataxia, and rapid neurologic deterioration (1,2). LD is caused by mutations in the EPM2A gene encoding laforin, a dual specificity protein phosphatase, or in the NHLRC1 gene encoding malin, an E3 ubiquitin ligase (3–7). Both laforin and malin are ubiquitously expressed (3, 5), associated with the mitochondria, endoplasmic reticulum, Golgi apparatus, and the neuronal processes (15). Preliminary histochemical investigations have also suggested the possible presence of neurofibrillary tangles (NFTs) in the knock-out mice (17). In this study, we have characterized the biochemical properties of Tau protein in the animal model of LD and identified laforin as an interacting partner of Tau. Our study identifies laforin to be one of the critical regulators of Tau protein and suggests that the Tau pathology might underlie some of the symptoms seen in LD.

EXPERIMENTAL PROCEDURES

Mice and Tissue Harvesting—The characterization of laforin-deficient mice has been described previously (15). The animals were maintained at the RIKEN Brain Science Institute animal facilities according to the Institute guidelines for the
Hyperphosphorylation of Tau in Laforin-deficient Mice

treatment of experimental animals. Animals of 4-, 6-, or 10-month-old age groups were sacrificed by cervical dislocation, and selected tissues were dissected and fixed in appropriate fixatives or quickly frozen in liquid nitrogen and stored at −80 °C until further analysis.

Tissue Extraction and Subcellular Fractionation—Brain and muscle tissues were homogenized in Tris-buffered saline containing protease and phosphatase inhibitors and used for immunoblotting analysis. The Sarkosyl-soluble and -insoluble fractions of NFTs were extracted as described (18).

Antibodies—The following monoclonal antibodies, obtained as gifts from Dr. Peter Davies, were used for detecting the Tau protein: CP13 for phospho-Ser202 Tau, PHF1 for phosphoSer396 Tau, and TGF5 for all forms of Tau. In addition, antibodies from Innogenetics (antibody AT8) and GenScript for the detection of phospho-Ser202 and an antibody from Epitomics (antibody E178) for the detection of phospho-Ser396 were also used. Antibodies for Gsk3β, phospho-Ser9 Gsk3β, protein kinase B (AKT), and Ser473 phospho-AKT were purchased from Cell Signaling Technology. Antibodies for protein phosphatase 2A (PP2A), Tyr307 phospho-PP2A, cyclin-dependent kinase 5 (CDK5), Ser159 phospho-CDK5, protein kinase A (PKA), Ser196 phospho-PKA, and PP1 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-GFP and anti-Myc tag antibodies were purchased from Roche Applied Science, and anti-γ-tubulin, anti-FLAG, and anti-V5 antibodies were from Sigma. Anti-ubiquitin antibody was purchased from Dako, and the secondary antibodies were obtained from Jackson Immunoresearch. Anti-laforin antibody was raised in rabbits using a synthetic peptide corresponding to amino acid residues 85–100 of the murine laforin sequence.

Immunohistochemical and Histopathological Analyses—Immunohistochemical analysis was done on formalin-fixed, paraffin-embedded sections and was reacted with appropriate antibody, as described previously (8, 15). They were visualized for light microscopy using diaminobenzidine-conjugated avidin-biotin complex kit (Vectastain ABC Elite; Vector Laboratories). For immunofluorescence staining, sections were processed with appropriate secondary antibodies that were conjugated with rhodamine or fluorescein isothiocyanate and visualized using an epifluorescence microscope, as described (8, 15). Bielschowsky’s silver staining was done on paraffin embedded brains sections as described previously (19).

Ultrastructural Analysis—For electron microscopy studies, the Sarkosyl-insoluble materials, isolated from the laforin-deficient mice, were mildly sonicated and dispersed in phosphate-buffered saline. For negative staining, the samples were first absorbed onto glow-discharged supporting membranes on 300-mesh grids and then treated with 2% uranyl acetate, dried, and observed with a FEI Tecnai 20 U Twin electron microscope. For immunogold labeling, the samples were prefixed by floating the grids on drops of 4% paraformaldehyde in 0.1 M phosphate buffer for 5 min. After washing, the grids were incubated with primary antibody followed by 10-nm colloidal gold-conjugated secondary antibody and processed for negative staining with 2% sodium phosphotungstic acid and observed as described (20).

Expression Constructs—The expression vectors containing Myc- or GFP-tagged wild-type or mutant forms of laforin were described previously (7, 8). Expression constructs for the FLAG-tagged laforin were generated by cloning the coding regions of the EPM2A gene into the pcDNA expression vector (Invitrogen). The short hairpin RNA knockdown constructs for the Epm2a gene were purchased from Open Biosystems and validated in one of our recent studies (8). The expression constructs for V5-tagged Tau and its mutant form were generously provided by Dr. Michael Hutton.

Cell Culture, Transfection, and Pull-down Assays—COS-7 or Neuro2A cells grown in Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% (v/v) fetal calf serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. All cells were grown at 37 °C in 5% CO2. Transfections were performed using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s protocol. Neuro2A cells were differentiated into neurons by culturing them in 1% fetal bovine serum as described (21). To establish the physical interaction between laforin and Tau proteins, we used the expression construct that code for polyhistidine-tagged Tau (22). Lysates of cells that had expressed His-tagged Tau with desired protein were incubated with Ni2+-affinity resin (Sigma) for 2 h at 4 °C and processed for pull-down assays as recommended by the manufacturer. Pulled down products were detected by immunoblotting using specific antibodies.

In Vitro Dephosphorylation Assay—The histidine-tagged Tau protein, transiently overexpressed in COS-7 cells, was hyperphosphorylated by treating the cells with wortmannin and affinity-purified using nickel resins. Similarly, the His-tagged laforin or its mutant Q293L was expressed and purified as described (23). The nickel resin-bound Tau was mixed with wild-type laforin or its mutant in the phosphatase assay buffer (50 mM HEPES, pH 6, 50 mM NaCl, 5 mM EDTA, 50 mM β-mercaptoethanol) and incubated for 2 h at 37 °C. A control reaction was performed in parallel, wherein the Tau protein was incubated with nickel resins treated with cell lysates that did not express His-tagged laforin. The reaction products were finally mixed with SDS sample buffer, boiled, and analyzed by immunoblotting.

Immunoprecipitation—Tissue or cell lysates were preincubated with protein G-Sepharose (Bangalore Genei, India) for 2 h at 4 °C and then incubated with anti-laforin or anti-GSK3β antibody (as indicated) for 1 h at 4 °C. After incubation, protein G-Sepharose was used for precipitation. The beads were washed with lysis buffer four times and then eluted with SDS sample buffer for immunoblot analysis as described (24).

GSK3β Activity Assay—GSK3β activity was measured as described previously (25) after immunoprecipitation of GSK3β from 100 μg of protein. Immobilized immune complexes were washed twice with lysis buffer and twice with kinase reaction buffer and incubated with phosphoglucogen synthase peptide-2 substrate (Upstate Biotechnology) and [γ-32P]ATP for 30 min at 30 °C. After this incubation, an aliquot of samples was placed on phosphocellulose disc (Whatman 31ET CHR filter paper), air-dried, and washed three times in 0.75% phosphoric acid and once with acetone. Radioactivity in the phosphocellulose disc was counted in a β-counter (PerkinElmer Life Sciences).
**Immunoblotting Analysis**—Protein samples were run on a 10% SDS-PAGE and transferred onto a nitrocellulose filter (MDI, India) as described previously (7, 8). Signal intensity of the immunoblot was quantitated using NIH Image software (Image; National Institutes of Health).

**RESULTS**

The characterization of laforin-deficient mice was reported in one of our previous publications (15). The present investigation was carried out on the C57BL/6 isogenic line for the Epm2a gene knock-out, derived by back-crossing the F1 heterozygous mutants with C57BL/6 animals through 11 generations, and the animals were genotyped as described (15).

**Neurofibrillary Tangles Observed in Laforin-deficient Mice**—Our investigations on the neuropathological changes in the brain sections of the 10-month-old laforin-deficient mice have suggested the presence of neurofibrillary tangles (NFTs), as revealed by Bielschowsky’s silver staining (Fig. 1, A–C). This was subsequently confirmed by immunohistochemical staining with antibodies E178 (26) and AT8 (27, 28) that specifically recognize Tau protein phosphorylated at Ser396 or Ser202 residues, respectively (Fig. 1, D–F). Numerous neurons that were positive for the dyes or the phospho-Tau antibodies were seen primarily in the hippocampus, thalamus, cerebral cortex, cerebellum, and brain stem of the laforin-deficient mice but not in the corresponding regions of the wild-type littermates (Fig. 1, A–I). Identical observations were made with antibodies CP13 and PHF1 as well (supplemental Fig. S1, A–D). The NFTs in laforin-deficient mice also stained intensely with ubiquitin antibody (supplemental Fig. S1, E–G). NFTs were not observed in the 2-, 4-, or 6-month-old knock-out mice analyzed.

In addition to brain, Tau protein is known to express in muscle tissues (29, 30). We have therefore checked for the presence of hyperphosphorylation of Tau protein in the muscle tissues of the 10-month-old laforin-deficient mice. Phospho-Tau-specific antibodies identified immunoreactive cytoplasmic inclusions in the muscle sections from the knock-out mice but not the wild-type littermates (Fig. 1, J–M). Such inclusions were not seen in the muscle sections of 4- and 6-month-old knock-out mice.

**Biochemical and Ultrastructural Characterization of Tau in Laforin-deficient Mice**—Consistent with the immunohistochemical observations, immunoblot analysis of Tau protein from the 10-month-old animals showed a significant increase in the phosphorylation levels at the Ser202 and Ser396 positions, both in muscle and brain tissues of the laforin-deficient mice, as compared with the wild-type littermates (Fig. 2, A and B, and supplemental Fig. S2A). This difference, however, was not obvious in the 4-month-old mice (Fig. 2A). The phosphorylation levels of Tau were nearly the same in wild-type and heterozygous animals of the 10-month age group (supplemental Fig. S2C). Because Tau is known to form insoluble aggregates upon hyperphosphorylation (31, 32), we further assessed the amount of Tau in the Sarkosyl-insoluble fractions derived from the brain and muscle tissues of the 10-month-old animals. A large amount of insoluble and phosphorylated forms of Tau was recovered from the brain and muscle tissue lysates of the laforin-deficient mice as compared with lysates of wild-type littermates (Fig. 2C). The Sarkosyl-insoluble material recovered from the laforin-deficient mice was further investigated with transmission electron microscopy. The NFTs observed in the Sarkosyl-insoluble fraction appeared to be straight filaments of about 10–20 nm in diameter (Fig. 2D). Labeling with antibodies against phosphorylated Tau (Ser396) revealed reasonably abundant Tau-containing filaments in the preparation (Fig. 2E and F). Such filaments were not seen in the preparations obtained from the age-matched wild-type littermates (data not shown), and the gold particles were not seen when the primary antibody was omitted for the immunodetection for the samples from the knock-out mice (data not shown). Taken together, the biochemical and ultrastructural analyses strongly suggest the presence of NFT-like Tau aggregates in the brain and muscle tissue of the laforin-deficient mice.

**Changes in the Phosphorylation Status of Tau Kinases and Tau Phosphatases in Laforin-deficient Mice**—Having established the difference in the phosphorylation levels of Tau pro-
Hyperphosphorylation of Tau in Laforin-deficient Mice

A brain and muscle tissue lysates of 4- (4 MO) or 10-month-old (10 MO) Epm2a knock-out (KO) or the wild-type (WT) littermates were evaluated by using antibodies that detect changes in the phospho form (CP13 and PHF1) or the total form of Tau protein (TGF5) by immunoblotting, as indicated. B, bar diagram showing the difference in the signal intensity of different forms of Tau, as indicated. Each bar represents average values ± S.D. of immunoblot analyses (*n = 4; **, p < 0.005). C, the detergent-insoluble Tau from brain and muscle tissues of 10-month-old animals were immunoblotted with (CP13, PHF1, and TGF5) antibodies raised against distinct forms of Tau, as indicated. D, electron microscopic analysis of Sarkosyl-insoluble NFTs isolated from the 10-month-old laforin-deficient mice as revealed by negative staining with 2% uranyl acetate. Most NFTs appeared to be straight filaments. E, purified NFTs were immunolabeled with an antibody against the Ser396 phospho-Tau, followed by negative staining with phosphotungstic acid. The phospho-Tau antibody was detected with a 10-nm gold particle-conjugated secondary antibody. Scale bar, 50 nm.

FIGURE 2. Biochemical and electron microscopic analyses of Tau protein in laforin-deficient mice. A, brain and muscle tissue lysates of 4- (4 MO) or 10-month-old (10 MO) Epm2a knock-out (KO) or the wild-type (WT) littermates were evaluated by using antibodies that detect changes in the phospho form (CP13 and PHF1) or the total form of Tau protein (TGF5) by immunoblotting, as indicated. B, bar diagram showing the difference in the signal intensity of different forms of Tau, as indicated. Each bar represents average values ± S.D. of immunoblot analyses (*n = 4; **, p < 0.005). C, the detergent-insoluble Tau from brain and muscle tissues of 10-month-old animals were immunoblotted with (CP13, PHF1, and TGF5) antibodies raised against distinct forms of Tau, as indicated. D, electron microscopic analysis of Sarkosyl-insoluble NFTs isolated from the 10-month-old laforin-deficient mice as revealed by negative staining with 2% uranyl acetate. Most NFTs appeared to be straight filaments. E, purified NFTs were immunolabeled with an antibody against the Ser396 phospho-Tau, followed by negative staining with phosphotungstic acid. The phospho-Tau antibody was detected with a 10-nm gold particle-conjugated secondary antibody. Scale bar, 50 nm.

Laforin physically interacts with and dephosphorylates the Tau protein. —Since the loss of laforin led to the hyperphosphorylation of Tau, we next explored the possibility that laforin, being a protein phosphatase, directly interacts with and dephosphorylates Tau. For this, polyhistidine-tagged Tau was transiently coexpressed with green fluorescent protein (GFP)-tagged laforin or GFP in COS-7 cells, and lysates were analyzed by nickel affinity bead pull-down assays. As can be seen in Fig. 4, Tau was able to pull down GFP-laforin and not the GFP, thus establishing the specific and physical interaction between laforin and Tau proteins. We next determined the domain of laforin that interacted with Tau. For this, we created constructs that code for either the CBD or the DSPD of the laforin protein with the FLAG tag at the amino terminal (see Fig. 4C). His-tagged Tau was coexpressed with FLAG-tagged full-length laforin or its truncated forms (CBD or the DSPD) in COS-7 cells and processed for nickel affinity pull-down assays. As shown in Fig. 4B, Tau was able to pull the full-length laforin and the DSPD of laforin, but the truncated peptide having the CBD was not detected in the pulled-down products, suggesting that laforin interacts with Tau through its phosphatase domain. We have also checked the interaction between endogenous Tau and laforin using a coimmunoprecipitation approach. For this, we have used the brain tissue lysates from 10-month-old animals, pulled laforin using anti-laforin antibody, and checked for the presence of Tau protein in the pull-down products. As shown in Fig. 4D, Tau was detected in the pulled-down product from the wild-type tissue and not in the tissues from the laforin-deficient mice, confirming the interaction between laforin and Tau proteins and the specificity of the assay employed. Having confirmed a direct physical interaction between laforin and Tau proteins, we next examined whether phosphorylated Tau is a substrate for laforin. For this, the wild-type Tau was expressed either alone or with laforin or an empty vector (control) in COS-7 cells and treated with wortmannin, a known inducer for Tau hyperphosphorylation (37). Similarly, a Tau missense mutant (P301L), which is...
known to become hyperphosphorylated when overexpressed (31), was expressed either alone or with laforin. As shown in Fig. 5A, coexpression of laforin resulted in a significant reduction in the cellular levels of Ser396 phospho form of both wild-type and the mutant Tau. Similarly, knockdown of laforin in a differentiated neuroblastoma cell line (Neuro2A) led to increased phosphorylation at the Ser396 residue of endogenous Tau (Fig. 5B). To finally confirm that Tau is indeed a direct substrate of laforin, hyperphosphorylated Tau was purified and incubated with wild type or the mutant form of laforin, and the phosphorylation status at Ser396 residue of Tau was evaluated by immunoblotting. Incubation of wild-type laforin with hyperphosphorylated Tau showed a significant reduction in the phosphorylation level at the Ser396 residue as compared with reactions with the mutant laforin or the mock control (Fig. 5C and D). These in vitro studies, in addition to replicating the findings in the laforin-deficient mice, have established that laforin indeed dephosphorylates the Ser396 residue of Tau, and thus it is a Tau phosphatase. Knockdown of laforin or its overexpression did not alter the phosphorylation status of GSK3β at the Ser9 position in the Neuro2A cell line (supplemental Fig. S2, D–E), suggesting that the observed difference in the phosphorylation status of GSK3β in the laforin-deficient mice could be a secondary effect and could be due to the physiological changes associated with loss of laforin in mice.
**Hyperphosphorylation of Tau in Laforin-deficient Mice**

**A.** pcDNA, Laforin, Tau (WT), Tau-P301L, Wortmannin, anti-Ser396 Tau, anti-Tau (total), anti-laforin.

**B.** Vector, RNAi-Epm2a, anti-Ser396 Tau, anti-tau (total).

**C.** Tau (WT), pcDNA, Laforin (WT), Laforin (Q293L), anti-Ser396 Tau, anti-Laforin, Anti-Tau (total).

**D.** Signal intensity for Ser396 tau (arbitrary value).

**FIGURE 5. Laforin dephosphorylates Tau protein at Ser396 residue.** A, wild-type Tau or its mutant (P301L) was coexpressed with a construct for laforin or an empty vector in COS-7 cells and analyzed for the difference by immunoblotting with PHF1 antibody, as indicated. COS-7 cells expressing wild-type Tau were treated with wortmannin to induce hyperphosphorylation of Tau. B, Neuro2A cells were transfected with empty vector (vector; lanes 1 and 2), or the short hairpin RNA interference construct to silence the Epm2a gene (RNAi-Epm2a; lanes 3 and 4), differentiated into neurons, and analyzed for changes in the phospho form of endogenous Tau by immunoblotting with PHF1. The efficiency of Epm2a knockdown was previously established by immunoblotting with anti-laforin antibody (8). C, Tau, laforin, and laforin mutant were overexpressed in COS-7 cells, affinity-purified, and used for the in vitro dephosphorylation assay as indicated. Resins incubated with empty vector transfected (pcDNA) cells were used as control. The reaction was arrested and immunoblotted with antibodies as indicated, as discussed under “Experimental Procedures.” D, bar diagram showing the difference in the signal intensity of bands detected by PHF1 antibody in the in vitro dephosphorylation assay done with the wild-type laforin, its mutant (Q293L), or the control resin (pcDNA). Each bar represents average values ± S.D. (n = 3; **, p < 0.005).

**DISCUSSION**

In this report, we demonstrate that the loss of laforin leads to accumulation of hyperphosphorylated Tau as NFTs in the LD mice model. The observed NFTs were ubiquitinated and detergent-insoluble, as known in Alzheimer disease (18, 38, 39), and such forms were abundant in the 10-month-old knock-out mice, suggesting a progressive deterioration of brain function. The regions that were positive for the NFTs strongly correlated with the sites of laforin expression (40). NFTs were not seen in the heterozygote littermates, suggesting that the complete loss of laforin is required for its formation in LD. Curiously, Lafora bodies and neuronal cell death, the other two neuropathological changes observed in the knock-out mice, predate the NFT formation (15–17). Thus, the progressive onset of the LD-like symptoms observed in laforin-deficient mice seems to correlate well with the age-dependent deposition of NFTs in the brain (15). NFTs have also been reported in LD patients (41); thus, abnormal regulation of Tau protein appears to be one of the common neuropathological changes associated with LD in humans and mice. Intriguingly, Tau straight filaments have also been described in Alzheimer and Pick diseases (42, 43). Thus, the NFTs are likely to underlie a subset of symptoms of LD, like dementia, which is known in tauopathies as well (2).

One of the significant findings of the present study was the observation of NFTs in the muscle tissues of the laforin-deficient mice. NFTs in the skeletal muscle are known in several forms of myopathies that are characterized by progressive muscle weakness and atrophy (44, 45). Although muscular atrophy is known in human LD (2), inclusions other than Lafora bodies in muscle have not yet been reported. Pending such findings, our present set of observations, together with our earlier report on muscular weakness in this LD mouse model (15), suggest that the Tau-positive inclusions could underlie some of the deficits of muscle functions seen in LD.

In determining which kinase or phosphatase is involved in the hyperphosphorylation of Tau in laforin-deficient mice, we show here that the level of the Ser9-phospho (inactive) form of GSK3β was lower in the 10-month-old knock-out mice. However, no changes in the level of the protein or in the phosphorylation levels were observed for several other players that are known to regulate the phosphorylation of Tau protein. Thus, the overactive GSK3β could be one of the triggers for the formation of NFTs in LD mice. Our observations on the GSK3β phosphorylation in the laforin-deficient mice and in cellular models contradict the report of Wang et al. (46) that the Ser9 residue of GSK3β was dephosphorylated by laforin phosphatase and support an earlier report that GSK3β is not a substrate of laforin (11). Since there is a reduction in the phospho form of GSK3β in the knock-out mice, laforin probably acts upstream of this key enzyme. AKT, PKA, and PP1 are a few of the known regulators of the Ser9 residue of GSK3β (36, 48, 49), and all three of them did not show a significant change in the phosphorylation level in the laforin-deficient mice. It would therefore be of interest to look for other regulators of GSK3β in the laforin-deficient mice.

Because laforin is a dual specificity phosphatase (4), we have also tested the possibility whether Tau could be a substrate for laforin. We demonstrate here that laforin physically interacts with Tau and that the interaction could perhaps be limited to the phosphatase domain of laforin. Consistent with the findings in the laforin-deficient mice, we show here with cellular models that coexpression of laforin with Tau decreases the phospho-Tau levels and that knockdown of laforin leads to an increase in the phospho form of Tau. Direct evidence for laforin being a Tau phosphatase came from the in vitro dephosphorylation assay. Thus, laforin might dephosphorylate Tau, at least at the Ser396 residue, under appropriate physiological signals. Mutations resulting in the loss of laforin, its phosphatase activity, or its interaction with Tau would lead to hyperphosphorylation of Tau and the NFTs, as seen in the LD mice. It would be of much interest now to check the level and/or activity of laforin in tauopathies like Alzheimer disease.

Tau phosphorylation reflects a critical balance between Tau kinase and Tau phosphatase activities. We show here that loss of laforin is associated with an increase in the levels of active form of GSK3β in the LD model. Thus, NFTs in LD may both involve activation of the Tau kinase (GSK3β) and the inactivation of a Tau phosphatase (laforin). GSK3β is known to act on Tau either individually or as a complex in the Alzheimer disease condition (35, 50). The activation of GSK3β in LD draws striking parallels with Alzheimer disease. Another element for Tau pathology in LD could be the Lafora polyglucosan bodies. Alterations in the glucose metabolism are associated with abnormal Tau phosphorylation (47, 51). Lafora bodies are thought to result from abnormal glyco-gen metabolic pathways (1, 11, 15, 16); therefore, a role for these inclusions in the genesis of NFTs cannot be ruled out.

In summary, we demonstrate here that loss of laforin leads to Tau hyperphosphorylation and NFTs, that laforin could be a crit-
ical regulator of Tau phosphorylation, and that the abnormal hyperphosphorylation of Tau might underlie some of the symptoms in LD. This study thus provides novel insight into the molecular basis of LD and has important implications on the formation of NFTs in tauopathies.

Acknowledgments—We thank Dr. Peter Davies (Albert Einstein College of Medicine) for the anti-Tau antibodies and Dr. Michael Hutton (Mayo Clinic College of Medicine) for the Tau expression constructs. We also thank Dr. Takumi Akagi (RIKEN Brain Science Institute, Wako-shi) and Dr. Gouthama (IIT Kanpur) for help and advice with the electron microscopy.

REFERENCES

1. Ganesh, S., Puri, R., Singh, S., Mittal, S., and Dubey, D. (2006) J. Hum. Genet. 51, 1–8
2. Van Heycop, D. E., and Jager, H. (1963) Epilepsia 4, 95–119
3. Minassian, B. A., Lee, J. R., Herbrick, J. A., Huizenga, J., Soder, S., Mungall, A. J., Dunham, I., Gardner, R., Fong, C. Y., Carpenter, S., Jardim, L., Satishchandra, P., Andermann, E., Sneed, O. C., 3rd, Lopes-Cendes, I., Tsui, L. C., Delgado-Escueta, A. V., Rouleau, G. A., and Scherer, S. W. (1998) Nat. Genet. 20, 171–174
4. Ganesh, S., Agarwala, K. L., Ueda, K., Akagi, T., Shoda, K., Usui, T., Hashikawa, T., Osada, H., Delgado-Escueta, A. V., and Yamakawa, K. (2000) Hum. Mol. Genet. 9, 2251–2261
5. Chan, E. M., Young, E. J., Ianzano, L., Munteanu, I., Zhao, X., Christopoulos, C. C., Avanzini, G., Elia, M., Ackerley, C. A., Vojvodic, J. N., Bohega, S., Andermann, E., Rouleau, G. A., Delgado-Escueta, A. V., Minassian, B. A., and Scherer, S. W. (2003) Nat. Genet. 35, 125–127
6. Gentry, M. S., Worby, C. A., and Dixon, J. E. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 8501–8506
7. Mittal, S., Dubey, D., Yamakawa, K., and Ganes (2007) Hum. Mol. Genet. 16, 753–762
8. Gentry, M. S., Worby, C. A., and Dixon, J. E. (2005) J. Biol. Chem. 280, 37526–37535
9. Iqbal, K., and Grundke-Iqbal, I. (1991) J. Neurochem. 55, 102, 11239–11244
10. Mirabella, M., Alvarez, R. B., Blak, M., Engel, W. K., and Askanas, V. (1996) J. Neurochem. Exp. Neurol. 55, 774–786
11. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Seglenenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W. L., Yen, S. H., Dickson, D. W., Davies, P., and Hutton, M. (2000) Nat. Genet. 25, 402–405
12. Bandyopadhyay, B., Li, G., Yin, H., and Kuret, J. (2007) J. Biol. Chem. 282, 16454–16464
13. Scher, S. W., and Yamakawa, K. (2001) Biochem. Biophys. Res. Commun. 283, 1333–1344
14. Greene, V., and Papasozomenos, S. C. (1987) J. Neurochem. Exp. Neurol. 46, 345
15. Perry, G., Mulvihill, P., Manetto, V., Autillo-Gambetti, L., and Gambetti, P. (1987) J. Neurosci. 7, 3736–3738
16. Kato, S., and Nakamura, H. (1990) Acta Neuropathol. 81, 125–129
17. Selcen, D., Ohno, K., and Engel, A. G. (2004) Brain 127, 433–451
18. Goebel, H. H., and Müller, H. D. (2006) Semin. Pediatr. Neurol. 13, 96–103
19. Wang, Y., Liu, Y., Wu, C., Zhang, H., Zheng, Z., Geiger, T. L., Zhang, P. (2006) Cancer Cell 10, 179–190
20. Planell, E., Tatebayashi, Y., Miyasaka, T., Liu, L., Wang, L., Herman, M., Yu, W. H., Luchsinger, J. A., Wadzinska, B., Duff, K. E., and Takashima, A. (2007) J. Neurosci. 27, 13635–13648
21. Fang, X., Yu, X. S., Lu, Y., Bast, R. C., Jr., Woodward, J. R., and Mills, G. B. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 11960–11965
22. Szatmari, E., Habas, A., Yang, P., Zheng, J. J., Hagg, T., and Hetman, M. (2005) J. Biol. Chem. 280, 37526–37535
23. Sato, S., Tatebayashi, Y., Akagi, T., Chui, D. H., Murayama, M., Miyasaka, T., Planell, E., Tanemura, K., Sun, X., Hashikawa, T., Yoshioka, K., Ishiguro, K., and Takashima, A. (2002) J. Biol. Chem. 277, 42060–42065
24. Planell, E., Miyasaka, T., Launey, T., Chui, D. H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayashi, Y., and Takashima, A. (2004) J. Neurosci. 24, 2901–2411